Home Newsfeeds PMV Pharmaceuticals Q2 EPS $(0.38) Down From $(0.29) YoY

PMV Pharmaceuticals Q2 EPS $(0.38) Down From $(0.29) YoY

PMV Pharmaceuticals (NASDAQ:PMVP) reported quarterly losses of $(0.38) per share. This is a 31.03 percent decrease over losses of $(0.29) per share from the same period last year.

byBenzinga Newsdesk

August 9, 2022

1 minute read

PMV Pharmaceuticals (NASDAQ:PMVP) reported quarterly losses of $(0.38) per share. This is a 31.03 percent decrease over losses of $(0.29) per share from the same period last year.

Dollar General ‘A Top-Tier Retail Name’ – Bullish Analyst Upgrades Stock

By Nabaparna Bhattacharya

January 4, 3:10 PM

Barclays analyst Seth Sigman upgraded Dollar General Corporation (NYSE: DG) to Overweight from Equal Weight,

Atlantic Equities Maintains Overweight on Merck & Co, Raises Price Target to $110

By Benzinga Newsdesk

July 13, 5:01 AM

Atlantic Equities analyst Steve Chesney maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $105 to $110.

MRK

Revance Therapeutics Q2 Sales $28.40M Miss $28.45M Estimate

By Benzinga Newsdesk

August 9, 5:15 PM

Revance Therapeutics (NASDAQ:RVNC) reported quarterly sales of $28.40 million which missed the analyst consensus estimate of $28.45 million by 0.18 percent. This is a 51.03 percent increase over sales of $18.80 million

RVNC

Why ContextLogic Stock Is Getting Hammered

By Henry Khederian

April 11, 2:51 PM

ContextLogic Inc (NASDAQ: WISH) shares are trading lower by 22.96% to $0.32 Tuesday afternoon after the company announced a 1-for-30 reverse stock split. What Else?

WISH

PMV Pharmaceuticals Q2 EPS $(0.38) Down From $(0.29) YoY

Related Posts

Dollar General ‘A Top-Tier Retail Name’ – Bullish Analyst Upgrades Stock

Atlantic Equities Maintains Overweight on Merck & Co, Raises Price Target to $110

Revance Therapeutics Q2 Sales $28.40M Miss $28.45M Estimate

Why ContextLogic Stock Is Getting Hammered